Abstract
Cisapride is a new prokinetic agent that acts at gastric emptying, esophagic peristalsis and the pressure of the low esophagic sphincter. In the present study we grave Cisapride for 12 weeks to 34 patients with severe pathologic gastroesophageal reflux and/or peptic esophagitis. The results show an important improvement of the clinic, pH monitoring, endoscopic and histologic alterations.
MeSH terms
-
Cisapride
-
Esophagitis, Peptic / drug therapy*
-
Esophagitis, Peptic / physiopathology
-
Female
-
Gastric Emptying / drug effects
-
Gastric Juice / chemistry
-
Gastroesophageal Reflux / drug therapy*
-
Gastroesophageal Reflux / physiopathology
-
Humans
-
Hydrogen-Ion Concentration
-
Male
-
Peristalsis / drug effects
-
Piperidines / therapeutic use*
-
Serotonin Antagonists / therapeutic use*
Substances
-
Piperidines
-
Serotonin Antagonists
-
Cisapride